1,2,3-Triazole-Containing Compounds as Anti-Lung Cancer Agents: Current Developments, Mechanisms of Action, and Structure-Activity Relationship
- PMID: 34177578
- PMCID: PMC8226129
- DOI: 10.3389/fphar.2021.661173
1,2,3-Triazole-Containing Compounds as Anti-Lung Cancer Agents: Current Developments, Mechanisms of Action, and Structure-Activity Relationship
Abstract
Lung cancer is the most common malignancy and leads to around one-quarter of all cancer deaths. Great advances have been achieved in the treatment of lung cancer with novel anticancer agents and improved technology. However, morbidity and mortality rates remain extremely high, calling for an urgent need to develop novel anti-lung cancer agents. 1,2,3-Triazole could be readily interact with diverse enzymes and receptors in organisms through weak interaction. 1,2,3-Triazole can not only be acted as a linker to tether different pharmacophores but also serve as a pharmacophore. This review aims to summarize the recent advances in 1,2,3-triazole-containing compounds with anti-lung cancer potential, and their structure-activity relationship (SAR) together with mechanisms of action is also discussed to pave the way for the further rational development of novel anti-lung cancer candidates.
Keywords: anticancer; hybrid molecules; lung cancer; structure–activity relationship; triazole.
Copyright © 2021 Liang, Sun, Li, Hou and Gao.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures












Similar articles
-
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.Eur J Med Chem. 2019 Dec 1;183:111700. doi: 10.1016/j.ejmech.2019.111700. Epub 2019 Sep 16. Eur J Med Chem. 2019. PMID: 31546197 Review.
-
Recent updates on 1,2,3-triazole-containing hybrids with in vivo therapeutic potential against cancers: A mini-review.Eur J Med Chem. 2023 May 5;251:115254. doi: 10.1016/j.ejmech.2023.115254. Epub 2023 Mar 6. Eur J Med Chem. 2023. PMID: 36893627 Review.
-
The anti-breast cancer therapeutic potential of 1,2,3-triazole-containing hybrids.Arch Pharm (Weinheim). 2024 Mar;357(3):e2300641. doi: 10.1002/ardp.202300641. Epub 2023 Dec 18. Arch Pharm (Weinheim). 2024. PMID: 38110853 Review.
-
1,2,3-Triazole-containing hybrids with potential antibacterial activity against ESKAPE pathogens.Eur J Med Chem. 2022 Dec 15;244:114888. doi: 10.1016/j.ejmech.2022.114888. Epub 2022 Oct 29. Eur J Med Chem. 2022. PMID: 36334453 Review.
-
Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities.Curr Top Med Chem. 2020;20(16):1461-1467. doi: 10.2174/1568026620666200128144825. Curr Top Med Chem. 2020. PMID: 31994464
Cited by
-
Discovery of a Series of Theophylline Derivatives Containing 1,2,3-Triazole for Treatment of Non-Small Cell Lung Cancer.Front Pharmacol. 2021 Oct 26;12:753676. doi: 10.3389/fphar.2021.753676. eCollection 2021. Front Pharmacol. 2021. PMID: 34764872 Free PMC article.
-
In-silico identification of small molecule benzofuran-1,2,3-triazole hybrids as potential inhibitors targeting EGFR in lung cancer via ligand-based pharmacophore modeling and molecular docking studies.In Silico Pharmacol. 2023 Aug 9;11(1):20. doi: 10.1007/s40203-023-00157-1. eCollection 2023. In Silico Pharmacol. 2023. PMID: 37575679 Free PMC article.
-
Structural Study of a La(III) Complex of a 1,2,3-Triazole Ligand with Antioxidant Activity.Antioxidants (Basel). 2023 Oct 17;12(10):1872. doi: 10.3390/antiox12101872. Antioxidants (Basel). 2023. PMID: 37891952 Free PMC article.
-
Signature of click chemistry in advanced techniques for cancer therapeutics.RSC Adv. 2025 Apr 4;15(14):10583-10601. doi: 10.1039/d5ra01196e. eCollection 2025 Apr 4. RSC Adv. 2025. PMID: 40190630 Free PMC article. Review.
-
In Silico Evaluation of Quinolone-Triazole and Conazole-Triazole Hybrids as Promising Antimicrobial and Anticancer Agents.Int J Mol Sci. 2025 Jul 14;26(14):6752. doi: 10.3390/ijms26146752. Int J Mol Sci. 2025. PMID: 40725000 Free PMC article.
References
-
- Abdallah W., Znati M., Regazzetti A., Dargère D., Laprévote O., Ben Jannet H., et al. (2017). Synthesis of S-Mono- and S,O-bis-1,2,3-triazole Linked 1,5-benzodiazepine Conjugates and Evaluation of Their Cytotoxic, Anti-tyrosinase, and Anti-cholinesterase Activities. Phosphorus, Sulfur, Silicon Relat. Elem. 192 (7), 835–844. 10.1080/10426507.2017.1287704 - DOI
-
- Battula K. S., Narsimha S., Thatipamula R. K., Reddy Y. N., Nagavelli V. R. (2017). Synthesis and Biological Evaluation of (N-(3-methoxyphenyl)-4-((aryl-1H -1,2,3-Triazol-4-Yl)methyl)thiomorpholine-2-Carboxamide 1,1-Dioxide Hybrids as Antiproliferative Agents. ChemistrySelect 2, 9595–9598. 10.1002/slct.201701902 - DOI
-
- Bistrovic A., Grbcic P., Harej A., Sedic M., Kraljevic-Pavelic S., Kostrun S., et al. (2018). Small Molecule Purine and Pseudopurine Derivatives: Synthesis, Cytostatic Evaluations and Investigation of Growth Inhibitory Effect in Non-small Cell Lung Cancer A549. J. Enzym. Inhib. Med. Chem. 33, 271–285. 10.1080/14756366.2017.1414807 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous